Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
apatinib + icotinib
- Development stage
- Phase 2
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of apatinib, a selective VEGFR-2 tyrosine kinase inhibitor with antiangiogenic properties, and icotinib, an EGFR tyrosine kinase inhibitor. This combination is primarily used to overcome resistance to EGFR-TKI monotherapy in patients with advanced non-small cell lung cancer.
02
Targets
EGFR (Epidermal growth factor receptor)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on apatinib + icotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on apatinib + icotinib.